SYNAGIS® PALIVIZUMAB

25+ YEARS OF CLINICAL EXPERIENCE
HELPING TO PROTECT HIGH-RISK INFANTS FROM RSV

2024-2025 Dosing Calendar | Every 28 Days[1,*]

Use this calendar to help schedule dosing and office appointments for your patients.

How to use the 28-day dosing calendar:
- Locate initial dosing date
- Move 1 box *down* (This will be 28 days later)
- Continue scheduling by moving *down* the same column

Key:
- ▢ Federal holidays in 2024-2025
- ▢ Weekends in 2024-2025

M	T	W	TH	F	S	SU	M	T	W	TH	F	S	SU	M	T	W	TH	F	S	SU	M	T	W	TH	F	S	SU
1 JUL	2 JUL	3 JUL	4 JUL	5 JUL	6 JUL	7 JUL	8 JUL	9 JUL	10 JUL	11 JUL	12 JUL	13 JUL	14 JUL	15 JUL	16 JUL	17 JUL	18 JUL	19 JUL	20 JUL	21 JUL	22 JUL	23 JUL	24 JUL	25 JUL	26 JUL	27 JUL	28 JUL
29 JUL	30 JUL	31 JUL	1 AUG	2 AUG	3 AUG	4 AUG	5 AUG	6 AUG	7 AUG	8 AUG	9 AUG	10 AUG	11 AUG	12 AUG	13 AUG	14 AUG	15 AUG	16 AUG	17 AUG	18 AUG	19 AUG	20 AUG	21 AUG	22 AUG	23 AUG	24 AUG	25 AUG
26 AUG	27 AUG	28 AUG	29 AUG	30 AUG	31 AUG	1 SEP	2 SEP	3 SEP	4 SEP	5 SEP	6 SEP	7 SEP	8 SEP	9 SEP	10 SEP	11 SEP	12 SEP	13 SEP	14 SEP	15 SEP	16 SEP	17 SEP	18 SEP	19 SEP	20 SEP	21 SEP	22 SEP
23 SEP	24 SEP	25 SEP	26 SEP	27 SEP	28 SEP	29 SEP	30 SEP	1 OCT	2 OCT	3 OCT	4 OCT	5 OCT	6 OCT	7 OCT	8 OCT	9 OCT	10 OCT	11 OCT	12 OCT	13 OCT	14 OCT	15 OCT	16 OCT	17 OCT	18 OCT	19 OCT	20 OCT
21 OCT	22 OCT	23 OCT	24 OCT	25 OCT	26 OCT	27 OCT	28 OCT	29 OCT	30 OCT	31 OCT	1 NOV	2 NOV	3 NOV	4 NOV	5 NOV	6 NOV	7 NOV	8 NOV	9 NOV	10 NOV	11 NOV	12 NOV	13 NOV	14 NOV	15 NOV	16 NOV	17 NOV
18 NOV	19 NOV	20 NOV	21 NOV	22 NOV	23 NOV	24 NOV	25 NOV	26 NOV	27 NOV	28 NOV	29 NOV	30 NOV	1 DEC	2 DEC	3 DEC	4 DEC	5 DEC	6 DEC	7 DEC	8 DEC	9 DEC	10 DEC	11 DEC	12 DEC	13 DEC	14 DEC	15 DEC
16 DEC	17 DEC	18 DEC	19 DEC	20 DEC	21 DEC	22 DEC	23 DEC	24 DEC	25 DEC	26 DEC	27 DEC	28 DEC	29 DEC	30 DEC	31 DEC	1 JAN	2 JAN	3 JAN	4 JAN	5 JAN	6 JAN	7 JAN	8 JAN	9 JAN	10 JAN	11 JAN	12 JAN
13 JAN	14 JAN	15 JAN	16 JAN	17 JAN	18 JAN	19 JAN	20 JAN	21 JAN	22 JAN	23 JAN	24 JAN	25 JAN	26 JAN	27 JAN	28 JAN	29 JAN	30 JAN	31 JAN	1 FEB	2 FEB	3 FEB	4 FEB	5 FEB	6 FEB	7 FEB	8 FEB	9 FEB
10 FEB	11 FEB	12 FEB	13 FEB	14 FEB	15 FEB	16 FEB	17 FEB	18 FEB	19 FEB	20 FEB	21 FEB	22 FEB	23 FEB	24 FEB	25 FEB	26 FEB	27 FEB	28 FEB	1 MAR	2 MAR	3 MAR	4 MAR	5 MAR	6 MAR	7 MAR	8 MAR	9 MAR
10 MAR	11 MAR	12 MAR	13 MAR	14 MAR	15 MAR	16 MAR	17 MAR	18 MAR	19 MAR	20 MAR	21 MAR	22 MAR	23 MAR	24 MAR	25 MAR	26 MAR	27 MAR	28 MAR	29 MAR	30 MAR	31 MAR	1 APR	2 APR	3 APR	4 APR	5 APR	6 APR
7 APR	8 APR	9 APR	10 APR	11 APR	12 APR	13 APR	14 APR	15 APR	16 APR	17 APR	18 APR	19 APR	20 APR	21 APR	22 APR	23 APR	24 APR	25 APR	26 APR	27 APR	28 APR	29 APR	30 APR	1 MAY	2 MAY	3 MAY	4 MAY
5 MAY	6 MAY	7 MAY	8 MAY	9 MAY	10 MAY	11 MAY	12 MAY	13 MAY	14 MAY	15 MAY	16 MAY	17 MAY	18 MAY	19 MAY	20 MAY	21 MAY	22 MAY	23 MAY	24 MAY	25 MAY	26 MAY	27 MAY	28 MAY	29 MAY	30 MAY	31 MAY	1 JUN
2 JUN	3 JUN	4 JUN	5 JUN	6 JUN	7 JUN	8 JUN	9 JUN	10 JUN	11 JUN	12 JUN	13 JUN	14 JUN	15 JUN	16 JUN	17 JUN	18 JUN	19 JUN	20 JUN	21 JUN	22 JUN	23 JUN	24 JUN	25 JUN	26 JUN	27 JUN	28 JUN	29 JUN
30 JUN	1 JUL	2 JUL	3 JUL	4 JUL	5 JUL	6 JUL	7 JUL	8 JUL	9 JUL	10 JUL	11 JUL	12 JUL	13 JUL	14 JUL	15 JUL	16 JUL	17 JUL	18 JUL	19 JUL	20 JUL	21 JUL	22 JUL	23 JUL	24 JUL	25 JUL	26 JUL	27 JUL

*Patients should receive SYNAGIS® (palivizumab) every 28 to 30 days throughout the respiratory syncytial virus (RSV) season. This calendar has been provided as a guide only and is not intended to be a substitute for, or have an influence on, the independent medical judgment of the healthcare professional.

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

- with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
- with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
- with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

LIMITATIONS OF USE

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

CONTRAINDICATIONS

Previous significant hypersensitivity reaction to SYNAGIS.

IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions: Anaphylaxis and anaphylactic shock (including fatal cases) and other severe acute hypersensitivity reactions have been reported. Permanently discontinue SYNAGIS and administer appropriate medication if such reactions occur.

Please see additional Important Safety Information on the next page. Click here for full Prescribing Information for SYNAGIS, including Patient Information.

2024-2025 Dosing Calendar | Every 30 Days[1],*

Use this calendar to help schedule dosing and office appointments for your patients.

How to use the 30-day dosing calendar:
- Locate initial dosing date
- Move 1 box *down* and 2 boxes to the *right* (This will be 30 days later)
- Continue scheduling by moving 1 box *down* and 2 boxes to the *right*

Key:
- Federal holidays in 2024-2025
- Weekends in 2024-2025

M	T	W	TH	F	S	SU	M	T	W	TH	F	S	SU	M	T	W	TH	F	S	SU	M	T	W	TH	F	S	SU
1 JUL	2 JUL	3 JUL	4 JUL	5 JUL	6 JUL	7 JUL	8 JUL	9 JUL	10 JUL	11 JUL	12 JUL	13 JUL	14 JUL	15 JUL	16 JUL	17 JUL	18 JUL	19 JUL	20 JUL	21 JUL	22 JUL	23 JUL	24 JUL	25 JUL	26 JUL	27 JUL	28 JUL
29 JUL	30 JUL	31 JUL	1 AUG	2 AUG	3 AUG	4 AUG	5 AUG	6 AUG	7 AUG	8 AUG	9 AUG	10 AUG	11 AUG	12 AUG	13 AUG	14 AUG	15 AUG	16 AUG	17 AUG	18 AUG	19 AUG	20 AUG	21 AUG	22 AUG	23 AUG	24 AUG	25 AUG
26 AUG	27 AUG	28 AUG	29 AUG	30 AUG	31 AUG	1 SEP	2 SEP	3 SEP	4 SEP	5 SEP	6 SEP	7 SEP	8 SEP	9 SEP	10 SEP	11 SEP	12 SEP	13 SEP	14 SEP	15 SEP	16 SEP	17 SEP	18 SEP	19 SEP	20 SEP	21 SEP	22 SEP
23 SEP	24 SEP	25 SEP	26 SEP	27 SEP	28 SEP	29 SEP	30 SEP	1 OCT	2 OCT	3 OCT	4 OCT	5 OCT	6 OCT	7 OCT	8 OCT	9 OCT	10 OCT	11 OCT	12 OCT	13 OCT	14 OCT	15 OCT	16 OCT	17 OCT	18 OCT	19 OCT	20 OCT
21 OCT	22 OCT	23 OCT	24 OCT	25 OCT	26 OCT	27 OCT	28 OCT	29 OCT	30 OCT	31 OCT	1 NOV	2 NOV	3 NOV	4 NOV	5 NOV	6 NOV	7 NOV	8 NOV	9 NOV	10 NOV	11 NOV	12 NOV	13 NOV	14 NOV	15 NOV	16 NOV	17 NOV
18 NOV	19 NOV	20 NOV	21 NOV	22 NOV	23 NOV	24 NOV	25 NOV	26 NOV	27 NOV	28 NOV	29 NOV	30 NOV	1 DEC	2 DEC	3 DEC	4 DEC	5 DEC	6 DEC	7 DEC	8 DEC	9 DEC	10 DEC	11 DEC	12 DEC	13 DEC	14 DEC	15 DEC
16 DEC	17 DEC	18 DEC	19 DEC	20 DEC	21 DEC	22 DEC	23 DEC	24 DEC	25 DEC	26 DEC	27 DEC	28 DEC	29 DEC	30 DEC	31 DEC	1 JAN	2 JAN	3 JAN	4 JAN	5 JAN	6 JAN	7 JAN	8 JAN	9 JAN	10 JAN	11 JAN	12 JAN
13 JAN	14 JAN	15 JAN	16 JAN	17 JAN	18 JAN	19 JAN	20 JAN	21 JAN	22 JAN	23 JAN	24 JAN	25 JAN	26 JAN	27 JAN	28 JAN	29 JAN	30 JAN	31 JAN	1 FEB	2 FEB	3 FEB	4 FEB	5 FEB	6 FEB	7 FEB	8 FEB	9 FEB
10 FEB	11 FEB	12 FEB	13 FEB	14 FEB	15 FEB	16 FEB	17 FEB	18 FEB	19 FEB	20 FEB	21 FEB	22 FEB	23 FEB	24 FEB	25 FEB	26 FEB	27 FEB	28 FEB	1 MAR	2 MAR	3 MAR	4 MAR	5 MAR	6 MAR	7 MAR	8 MAR	9 MAR
10 MAR	11 MAR	12 MAR	13 MAR	14 MAR	15 MAR	16 MAR	17 MAR	18 MAR	19 MAR	20 MAR	21 MAR	22 MAR	23 MAR	24 MAR	25 MAR	26 MAR	27 MAR	28 MAR	29 MAR	30 MAR	31 MAR	1 APR	2 APR	3 APR	4 APR	5 APR	6 APR
7 APR	8 APR	9 APR	10 APR	11 APR	12 APR	13 APR	14 APR	15 APR	16 APR	17 APR	18 APR	19 APR	20 APR	21 APR	22 APR	23 APR	24 APR	25 APR	26 APR	27 APR	28 APR	29 APR	30 APR	1 MAY	2 MAY	3 MAY	4 MAY
5 MAY	6 MAY	7 MAY	8 MAY	9 MAY	10 MAY	11 MAY	12 MAY	13 MAY	14 MAY	15 MAY	16 MAY	17 MAY	18 MAY	19 MAY	20 MAY	21 MAY	22 MAY	23 MAY	24 MAY	25 MAY	26 MAY	27 MAY	28 MAY	29 MAY	30 MAY	31 MAY	1 JUN
2 JUN	3 JUN	4 JUN	5 JUN	6 JUN	7 JUN	8 JUN	9 JUN	10 JUN	11 JUN	12 JUN	13 JUN	14 JUN	15 JUN	16 JUN	17 JUN	18 JUN	19 JUN	20 JUN	21 JUN	22 JUN	23 JUN	24 JUN	25 JUN	26 JUN	27 JUN	28 JUN	29 JUN
30 JUN	1 JUL	2 JUL	3 JUL	4 JUL	5 JUL	6 JUL	7 JUL	8 JUL	9 JUL	10 JUL	11 JUL	12 JUL	13 JUL	14 JUL	15 JUL	16 JUL	17 JUL	18 JUL	19 JUL	20 JUL	21 JUL	22 JUL	23 JUL	24 JUL	25 JUL	26 JUL	27 JUL

*Patients should receive SYNAGIS® (palivizumab) every 28 to 30 days throughout the RSV season. This calendar has been provided as a guide only and is not intended to be a substitute for, or have an influence on, the independent medical judgment of the healthcare professional.

IMPORTANT SAFETY INFORMATION (cont'd)

Coagulation Disorders: SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder.

RSV Diagnostic Test Interference: Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Serious Adverse Reactions: The most common serious adverse reactions occurring with SYNAGIS are anaphylaxis and other acute hypersensitivity reactions.

Most Common Adverse Reactions: The most common adverse reactions are fever and rash.

Postmarketing Experience: Severe thrombocytopenia and injection site reactions have been identified during post approval use of SYNAGIS.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These are not all the possible risks associated with SYNAGIS.

Please click here for full Prescribing Information for SYNAGIS, including Patient Information.

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or the FDA at 1-800-FDA-1088.

Reference: **1.** SYNAGIS (palivizumab) [prescribing information]. Waltham, MA: Sobi, Inc. 2021.

sobi